962 related articles for article (PubMed ID: 23328088)
21. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis.
Rohner A; Langenkamp U; Siegler U; Kalberer CP; Wodnar-Filipowicz A
Leuk Res; 2007 Oct; 31(10):1393-402. PubMed ID: 17391757
[TBL] [Abstract][Full Text] [Related]
22. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.
Huenecke S; Zimmermann SY; Kloess S; Esser R; Brinkmann A; Tramsen L; Koenig M; Erben S; Seidl C; Tonn T; Eggert A; Schramm A; Bader P; Klingebiel T; Lehrnbecher T; Passweg JR; Soerensen J; Schwabe D; Koehl U
J Immunother; 2010; 33(2):200-10. PubMed ID: 20145545
[TBL] [Abstract][Full Text] [Related]
23. The effects of IL-17 upon human natural killer cells.
Al Omar S; Flanagan BF; Almehmadi M; Christmas SE
Cytokine; 2013 Apr; 62(1):123-30. PubMed ID: 23490420
[TBL] [Abstract][Full Text] [Related]
24. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
25. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells.
Santourlidis S; Trompeter HI; Weinhold S; Eisermann B; Meyer KL; Wernet P; Uhrberg M
J Immunol; 2002 Oct; 169(8):4253-61. PubMed ID: 12370356
[TBL] [Abstract][Full Text] [Related]
26. NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML.
Schlegel P; Ditthard K; Lang P; Mezger M; Michaelis S; Handgretinger R; Pfeiffer M
J Immunol Res; 2015; 2015():473175. PubMed ID: 26236752
[TBL] [Abstract][Full Text] [Related]
27. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
28. Effect of cytarabine and decitabine in combination in human leukemic cell lines.
Qin T; Youssef EM; Jelinek J; Chen R; Yang AS; Garcia-Manero G; Issa JP
Clin Cancer Res; 2007 Jul; 13(14):4225-32. PubMed ID: 17634552
[TBL] [Abstract][Full Text] [Related]
29. Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.
Sohlberg E; Pfefferle A; Andersson S; Baumann BC; Hellström-Lindberg E; Malmberg KJ
Oncotarget; 2015 Oct; 6(33):34178-90. PubMed ID: 26497557
[TBL] [Abstract][Full Text] [Related]
30. The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
Zhou J; Li Y; Yao Y; Wang L; Gao L; Gao X; Luo X; Li J; Jiang M; Zhou M; Wang L; Yu L
Mol Med Rep; 2013 Nov; 8(5):1549-55. PubMed ID: 24002123
[TBL] [Abstract][Full Text] [Related]
31. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
Flotho C; Claus R; Batz C; Schneider M; Sandrock I; Ihde S; Plass C; Niemeyer CM; Lübbert M
Leukemia; 2009 Jun; 23(6):1019-28. PubMed ID: 19194470
[TBL] [Abstract][Full Text] [Related]
32. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation.
Schmiedel BJ; Arélin V; Gruenebach F; Krusch M; Schmidt SM; Salih HR
Int J Cancer; 2011 Jun; 128(12):2911-22. PubMed ID: 20960460
[TBL] [Abstract][Full Text] [Related]
33. KIR2DS3 is associated with protection against acute myeloid leukemia.
Shahsavar F; Tajik N; Entezami KZ; Fallah Radjabzadeh M; Asadifar B; Alimoghaddam K; Ostadali Dahaghi M; Jalali A; Ghashghaie A; Ghavamzadeh A
Iran J Immunol; 2010 Mar; 7(1):8-17. PubMed ID: 20371915
[TBL] [Abstract][Full Text] [Related]
34. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity.
Suck G; Branch DR; Smyth MJ; Miller RG; Vergidis J; Fahim S; Keating A
Exp Hematol; 2005 Oct; 33(10):1160-71. PubMed ID: 16219538
[TBL] [Abstract][Full Text] [Related]
35. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
[TBL] [Abstract][Full Text] [Related]
36. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
Bernson E; Hallner A; Sander FE; Wilsson O; Werlenius O; Rydström A; Kiffin R; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
Leukemia; 2017 Dec; 31(12):2552-2559. PubMed ID: 28529313
[TBL] [Abstract][Full Text] [Related]
37. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
38. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
39. Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.
Pettigrew KA; Armstrong RN; Colyer HA; Zhang SD; Rea IM; Jones RE; Baird DM; Mills KI
Genes Chromosomes Cancer; 2012 Aug; 51(8):768-80. PubMed ID: 22517724
[TBL] [Abstract][Full Text] [Related]
40. Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity.
Ghio M; Contini P; Negrini S; Boero S; Musso A; Poggi A
Eur J Immunol; 2009 Dec; 39(12):3459-68. PubMed ID: 19830740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
